COR vs REGN · P/E 21, rev $321.33B vs P/E 14, rev $14.34B
Cencora Inc. (COR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Cencora Inc. (COR) is a medical distribution company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported COR revenue for 2025-09-30 was $321.33B. Net income was $1.57B. Revenue was up 9.3% from 2024-09-30 to 2025-09-30. COR currently screens at market cap $53.91B and trailing P/E 21.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
COR currently screens at market cap $53.91B and trailing P/E 21.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the COR and REGN stock pages for the full models.
Not investment advice.